m+Medelevator.RU
← Поиск публикаций
Turkish neurosurgery · 2026

Effect of Electrical Capacitance-Based Therapy on the Viability of U87 and T98-G Glioblastoma Cell Lines.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Abat Eray, Bekci Hatice, Yerer Mukerrem Betul, Durmus Nimetullah Alper, Sahin Ali, Albayrak Serhat, Oral Sukru, Kucuk Ahmet, Ulutabanca Halil

Аннотация

AIM: To examine the selective cytotoxic effects of Electro-Capacitive Cancer Therapy (ECCT) on human glioblastoma (GBM) cell lines (U87-MG and T98-G) and to evaluate its impact on normal epithelial cells. MATERIAL and METHODS: U87-MG and T98-G glioblastoma cells, along with Beas-2B normal epithelial cells, were exposed to ECCT at 100 kHz frequency and 20 V for 24 hours. Cell viability was determined using the MTT assay, while morphological changes were assessed through phase-contrast microscopy. Statistical analyses were conducted using one-way ANOVA and Student's t-test, with statistical significance defined as p < 0.05. RESULTS: ECCT exposure caused a time-dependent reduction in the viability of both GBM cell lines. U87-MG cells showed significant inhibition at all exposure durations, whereas T98-G cells exhibited a marked decrease only after 24 hours (p < 0.0001). In contrast, Beas-2B cells maintained their morphology and viability, suggesting that ECCT selectively targets malignant cells while sparing normal epithelial cells. CONCLUSION: ECCT significantly inhibits glioblastoma cell proliferation without adversely affecting normal cells, highlighting its promise as a non-invasive adjunctive treatment option for GBM. Further preclinical and clinical studies are warranted to clarify its underlying mechanisms, optimize exposure parameters, and determine its potential integration into multimodal glioblastoma therapy.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты